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We seek to understand and treat cancer to reduce a major source of human
suffering. Cancer is a plague of our generation, one of the last incurable diseases. It is
interesting to note that past generations did not generally live long enough to suffer from
cancer. Infectious disease drastically limited the human life span. In recent history,
western medicine has been able to control infection and life expectancy has risen
dramatically. Cancer is the next hurdle. Modem research slowly gains insight with the
hope of finding new ways to control cancer.
This paper provides information about the process by which cancer develops and
how the disease can be treated. The paper begins with a discussion of the plausible
causes for cancer. Then, explanations of how cancer works at a cellular level will help
the reader think about cancer in the same framework as modem cancer researchers. Next,
some of the current pursuits of cancer research are explored. In order to provide more
specific information, the focus narrows to breast cancer. New discoveries and
experimental pursuits are discussed. The last section of this paper explains the process a
breast cancer patient might go through as breast cancer is diagnosed and treated.
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I. Causes of Cancer
A search of the literature will reveal countless studies that correlate a variety of
foods, chemicals, and lifestyle choices to increased or decreased rates of cancer. The list
of options that may relate to the frequency of cancer is long, and studies often conflict
with one another. Correlation studies are the only method for tracking the frequency of
cancer in a population, but correlation studies have their problems. Correlation does not
equal causation; A third factor may cause both elements in question, especially when the
supposed cause is a broad parameter. Nevertheless, there are a few major trends of
correlation studies that have stood up to hundreds of studies.
Tobacco is an undeniable cause of cancer. Smoking can cause cancer in the lung,
upper respiratory tract, esophagus, bladder, pancreas, stomach, liver, and kidney. It has
also been implicated in cancers of the colon, rectum, and leukemia. 30% of cancer
fatalities are due to smoking (Trichopoulos, 1996). Risk increases with the frequency
that a person smokes and the tar content of the cigarettes. Starting to smoke at a younger
age also increases the risk for cancer. The most important factor of all, however, is
duration. The longer a person smokes, the higher the risk for cancer. It is always
beneficial for people to quit smoking, regardless of age or number of years they have
smoked.
Diet is an equally serious predictor of cancer. A diet high in saturated fat and red
meat is associated with colon and rectal cancer. A poor diet and a smoking habit are so
often confounded that it is difficult to quantify the separate effects of these factors, but
together they are responsible for up to 60% of all cancer fatalities (Trichopoulos, 1996).
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Many other factors in the diet are responsible for certain types of cancer. Alcohol
has been shown to cause cancer in the upper respiratory tract, digestive tract, and liver,
and it may contribute to cancer of the breast, colon, and rectum. Excess salt has been
shown to cause stomach cancer. Also, populations of children in Southeast Asia who eat
salty fish have a high occurrence of cancer in the nasopharynx (Trichopoulos, 1996).
Coffee and artificial sweeteners, however, have not been linked to cancer in humans.
Experiments have shown the artificial sweeteners can induce tumors in lab animals, but
only in doses so high that no human could consume a dangerous amount.
Environmental and work related causes have also been proven. Asbestos,
benzene, formaldehyde, diesel exhaust, and radon are most toxic offenders. Workplace
regulations have successfully curbed cancers caused unsafe working conditions.
People often wonder if some races are more prone to cancer than others. The
current consensus is that there is not a racial predisposition that is due to genetic
difference. Many studies have compared the rate of cancer in separate races of people
and found that people of one race get cancer more than another race. However, these
results can always be explained by other confounding factors. For example, if many
members of a race live below the poverty line, they have an increased risk of dying from
cancer. The reason is poor medical attention, not anything pertaining to race. Diet and
lifestyle are other common factors that skew data. A study comparing women with breast
cancer found that women in Japan are one-fourth as likely to get breast cancer as
Americans. However, that same study showed that Japanese-Americans living in the
United States do not have a significantly different risk for breast cancer. The racial
difference was not the causative factor.
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All types of radiation have been tested for the possibility of causing cancer.
Studies conclude that electric and magnetic fields from power lines and household
appliances do not cause cancer, no matter how close a person lives to a generator. Cell
phones are another item that has come into question in recent years. Cell phones,
microwaves, wireless systems, and even living creatures emit electromagnetic radiation at
a higher level than power lines, but the photon energy is still several orders of magnitude
less than is necessary to ionize a molecule and possibly cause a mutation that could lead
to cancer. However, it is difficult to assess the compound effect of all of these factors.
Nuclear materials easily surpass the energetic threshold necessary to cause
mutations. Residents of Hiroshima and Nagasaki during World War II were exposed to
the most intense amounts of radiation ever observed in humans. One percent of the
victims who survived more than one year after the initial blast developed cancer
(Trichopoulus, 1996). This may be less than the general public expected, but considering
the body’s ability to correct mutations and the rare collection of mutations that are
necessary to cause cancer, this is an alarmingly high statistic. Nuclear energy plants, on
the other hand, do not pose the same risk to those nearby. Leukemia in not higher among
those who live next door to nuclear plants and children of nuclear plant workers do not
show a higher a higher rate of leukemia than the general public. The final example of
exposure to radiation is chemotherapy treatments for cancer. Ironically, medical
treatments that use radiation account for 1% of cancer fatalities. This is not an adequate
reason to shy away from a treatment that could save a patient’s life, but there is a risk.
Chemotherapy patients should actively screen for other types of cancer.
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Despite the many causes that can be correlated with cancer, some cancers are not
due to external influences. A very rough estimate suggests that nearly one-fourth of all
cancers occur independently of any of the above causes. Carcinogens within the body
and genetic mistakes that are not repaired also cause cancer.

II. Cancer at a Cellular Level
Cellular Growth
Cancer is the uncontrolled growth of a single cell. It is helpful to look at the
process of cell growth and division in normal cells to see how problems occur. In
normal, cellular growth, cells proceed through four stages of the cell cycle. The first
stage is G1 (Gap 1), a resting stage between growth. Next is S-phase, when the cell
synthesizes DNA, doubles all the organs, and grows. This is followed by G2 (Gap 2), a
second rest phase. The fourth stage is M-phase, when mitosis occurs and the cell divides
into two daughter cells. There are checkpoints in the cell cycle at G2, after M-phase, and
before S-phase begins. At each checkpoint, the cell can go back to the preceding stage to
correct or complete a step (Bailey, 1998). The cycle ensures that the cell won’t divide
before DNA has been properly replicated and the cell has grown.
A cell divides when chemical signals reach the outside of the cell and bind to
protein receptors on the surface of the cell. The signal gets relayed to the nucleus, which
begins to transcribe DNA into a protein. When growth factors bind to surface receptors,
the message for growth is received in the nucleus, and the DNA will transcribe a protein
to initiate cell growth. When growth-inhibiting factors bind to other surface receptors, a
different message is received in the nucleus, and DNA transcribes a protein responsible
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for inhibiting cell division. A cell only divides when messages from growth factors
outweigh messages from growth-inhibiting factors.
A cancerous cell has lost control of these constraints and divides indiscriminately.
Mutations in the receptors cause them to change so that the wrong messages are received.
Receptors are proteins with a signature shape and electrical charge. Only one type of
protein with the exact shape and charge will fit together with the receptor, like a key in a
lock. Problems occur when a mutation changes the shape or charge of the receptor. The
appropriate proteins will not bind and the wrong proteins may be able to bind in their
place. For example, a receptor for growth factors may change so that many different
kinds of protein are able to bind to it. The cell will be inundated with messages
promoting cell division. It will divide as fast as possible as long as proteins continue to
bind to the surface of the cell and send growth signals to the nucleus. The cell has
become cancerous. Receptors for growth inhibitors can also mutate to cause cancer. Any
change to these receptors would have dangerous implications. If growth-inhibiting
factors can not bind to surface receptors, the cell never receives any messages to stop
dividing. Recall that the nucleus receives a balance of positive and negative messages for
growth. If receptors for growth factors are normal but receptors for growth inhibitors
malfunction, the nucleus constantly receives a positive message for growth. The cell will
divide without limit.
Genetics
Cancer is ultimately due to changes in DNA that cause proteins to be translated
incorrectly. Proteins controlling initiation and inhibition of cell growth are not
functioning correctly, due to misinformation from genes. Several specific mutations on
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certain genes are necessary before a cell actually loses control of growth regulation. In
fact, most cancers require six or seven mutations before abnormal growth begins. The
first several mutations may cause a slight increase in cell growth that results in a benign
tumor. Additional mutations will cause more problems in growth regulation and
ultimately cause the cell to progress into a full-blown cancerous cell that is likely to
spread.
Scientists have classified genes that affect cancer into three categories:
oncogenes, tumor suppressor genes, and mutator genes. Oncogenes stimulate cell
proliferation. In cancer cells, they are more active than usual. Tumor suppressor genes
have lost their ability to inhibit cell division in cancer cells. Mutator genes are part of a
system to ensure DNA fidelity. They are involved with DNA replication and also correct
mistakes that are present after replication. DNA polymerase is an example of a protein
that corrects mistakes in the DNA as the DNA replicates. This system only leaves one
mistake for every 10^ or 10* base pairs. Other proteins correct mistakes after DNA
synthesis. These proteins can remove a mismatched base pair and replace it with the
correct nucleotide. They recognize the older of the two DNA strands and use it as a
template. Methyl groups attach to DNA over time, so proteins recognize the older
strands of DNA as the strand with methyl groups attached. If the newer DNA strand does
not match the older strand corrections will be made. With this system in place, the body
only leaves one mistake in every lO’ to 10‘°base pairs. Problems in the genes that cause
these proteins to malfunction make the cell more prone to mutation errors. More
mistakes get made and mistakes are left uncorrected.
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Mutator genes will not correct against mutations that have been inherited. The
correction system uses older (more methylated) DNA as a template to correct mistakes,
but would not alter DNA from these blueprints. The body would not identify hereditary
mutations as mistakes. As long as DNA replicates properly and the newly formed strand
of DNA is the same as older strands of DNA, the body will not identify a problem.
Harmful genes are often called mutations because they are different from others and they
cause a damaging condition, but they are an integrated part of a person’s genome. The
word “mutation” is sometimes used in this paper to denote a change in DNA, but other
times it refers to a problem that is hereditary.
When one mutation occurs in the cell’s DNA, it appears to increase the likelihood
that more mutations will occur and go uncorrected. This may be evidence that repair
systems become less efficient with age. Or, perhaps the cell receives so many signals to
divide that it rushes through checkpoints in the cell cycle and more mistakes happen this
way. It may also reflect damage to a gene that controls mutations, a mutator gene.
One example of a mutator gene is p53. When DNA is damaged, p53 brings the
cell cycle to halt and gives the cell time to repair DNA. If the DNA has been damaged
beyond repair, the cell will die in a process called apoptosis, or programmed death. The
p53 gene is instrumental in initiating programmed death. The function of the p53 gene is
supported by an experiment with genetically altered mice. Mice who were missing the
p53 gene on both alleles were viable and had no problems with growth. However, 75%
had cancer after six months and 100% had cancer after ten months (Russell, 1998). The
experiment showed that p53 is not necessary for growth, but has a definite role as a tumor
suppressor. If both alleles of the p53 gene have been inactivated, cells won’t stop to
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repair DNA and cells won’t die, no matter how much damage has been done to the DNA.
There are many ways that the p53 gene could be inactivated. At least seventeen proteins
interact with p53. Mutations in the p53 gene itself or in any of these proteins could stop
the activity of p53.
Mutations are random, rare events that build up in DNA over the course of a
lifetime. It is an incredibly unlikely occurrence when the six or seven specific mutations
that are necessary to produce a certain type of cancer occur in a single cell! In addition,
the body’s DNA repair systems must fail for each mutation. It takes time for mutations
to accme until one cell contains the unlucky combination. For this reason, cancers tend
to occur later in life.
Cancers that occur in younger patients tend to involve fewer genes. A cancer that
can be caused by only one or two mutations is a more likely event than a type of cancer
that requires six or seven mutations. When looking at general trends in a population, not
as much time passes before the unfortunate mutations occur when fewer genes are
involved. Retinoblastoma, cancer of the eye, is the most common cancer in young
children. True to the theory, retinoblastoma can be induced by a mutation in a single
gene. It is the only known cancer that involves only one gene. The gene responsible for
retinoblastoma, called RB+, is a tumor suppressor gene. When both alleles of the RB+
gene mutate, the cell loses control of growth regulation (Russell, 1998).
Heredity
It is possible to inherit one or more genes involved with cancer. A person
receives the mutated form of the gene in place of the normal form. Heredity is a strong
factor for retinoblastoma and it further explains why retinoblastoma occurs in young
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people. Many children inherit a recessive allele, RB, which does not operate properly.
They are healthy as long as the other allele for that gene functions correctly, but they
have a strong predisposition for cancer. RB, the mutated form of the gene, is present in
all of their cells. A mutation could occur in any of the cells to make the remaining allele
of the RB+ gene inoperable. The cells will begin to proliferate without limit and become
a tumor.
Some families pass along several genes that predispose people to cancer. For
example, a person could receive two or three of the mutations that cause familial
adenomatous polyposis (FAR), a type of colon cancer that requires at least six mutations
before the cell becomes a tumor that will spread to other parts of the body (Russell,
1998). A genetic predisposition for cancer is not a death sentence. There are still several
rare mutation events that must occur over the course of this person’s lifetime before the
cell becomes cancerous. Some members of the family will never suffer from cancer.
However, people who inherit mutations clearly have a head start toward acquiring cancer
and they tend to accrue all the necessary mutations earlier in life. When data is analyzed
for populations, the hereditary link of some cancers can be seen when younger patients
suffer from cancer.

111. Breast Cancer
Breast cancer is a common disease of out time. 185,000 new cases of breast
cancer are diagnosed each year. Over 46,000 women die each year from breast cancer.
In developed countries, women have a one-in-ten chance of being diagnosed for breast
cancer and the risk increases with age. The average age of onset is fifty-five (Russell,
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1998). Most statistics refer to breast cancer in women, but men suffer from breast cancer
as well.
Types of Breast Cancer
The anatomy of the breast consists of fifteen or twenty lobes arranged in a daisy
shape underneath the nipple. Each lobe has smaller lobules attached. Lx)bules end in
bulbs that produce milk. Ducts connect bulbs, lobules, and lobes to the nipple for
nursing. Lobes are surrounded by fatty tissue with lymph nodes dispersed throughout.
The lymphatic system is part of the immune system. A network or lymphatic
vessels and lymph nodes make, store, and disperse cells that fight infection. Intruding
cells get trapped in the lymphatic system and removed from the infected area. Lymph
nodes are found under the arms, behind the ears, in the abdominal cavity, in the groin,
behind the knee, and many places throughout the body.
There are two major types of breast cancer. Ductal carcinoma is cancer of the
ducts and lobular carcinoma is cancer of the lobules. If cancer reaches a lymph node and
metastasizes, or spreads, lymph nodes may carry it to the underarm, the area above the
collarbone, or many other sites in the body.
Hereditary Breast Cancer
It is possible to have a hereditary predisposition for breast cancer. If a firstdegree relative (mother or sister) has breast cancer, the patient is two to three times more
likely to get cancer. Cancer is likely to have a genetic factor when patients have cancer
early in life, if several family members have cancer, or when the disease affects both
breasts. The average age for patients with a genetic predisposition is forty-five to fortyseven, compared to age fifty-five in the general public. However, the prevalence of
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hereditary breast cancer should not be overstated. Only 5-10% of cancers may be due to
genetic inheritance. Most cases of breast cancer are sporadic (unrelated to hereditary).
Breast Cancer Genes
Two breast cancer genes have been discovered. The BRCAl gene was
discovered in 1994, followed by BRCA2 in 1995. One study showed that 80-90% of
people who have mutations in the BRCAl and BRCA2 genes will develop cancer
(Thorlacius, 1998). A population study in Iceland tried to assess the commonality of
mutations to the two breast cancer genes. One mutation in the BRCA2 gene occurred in
as much as 0.6% of the population (Thorlacius, 1998). These two genes are quite large
and many mutations are possible. Of course, only certain mutations to the BRCAl and
BRCA2 genes cause breast cancer. Most mutations that have been observed result in a
protein that is shorter than usual, suggesting a loss of function mutation. Studying these
two genes could provide information for other types of cancer. Mutations in these two
genes may cause ovarian, prostate, and colon cancers. Mutations in the BRCA2 gene
could also cause pancreatic cancer, laryngeal cancer, and malignant melanoma. The link
between each of these types of cancer is not understood at this time.

The Link to Estrogen
A collection of correlation studies provides evidence for the theory that
overexposure to estrogen causes breast cancer. Estrogen controls growth of secondary
sex characteristics, so it follows logically that overexposure to estrogen is associated with
abnormal growth in the breast. Young people who have excessive growth (height or
weight) at an early age have been correlated with a higher risk for breast cancer. Obesity
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at a young age also increases the risk. The most probable explanation for these two
phenomena is that these women menstruate earlier in life and are exposed to their body’s
own hormones for a longer duration. Obesity in adults does not cause a propensity for
breast cancer. (However, it does increase the risk for cancer in the endometrium, colon,
kidney, and gallbladder.) This suggests that early menstruation, or the exposure to
estrogen at a younger age, is the true culprit, not obesity. Early menarche and late
menopause are both predictors of breast cancer. In addition, women who receive
supplemental estrogen after menopause also have a higher rate of breast cancer.
Some environmental pollutants may cause cancer by a similar mechanism to
estrogen. Organic compounds that are ring shaped and contain chlorine have been shown
to cause cancer. These compounds are called xenoestrogens because of their structural
similarities to estrogen. Researchers propose that they mimic estrogen and stimulate cell
division in the breast and reproductive organs. These compounds are found in pesticides
like DDT. DDT, or Deet, is now illegal in the United States, but it is still used in many
other countries.
All this evidence led to the conclusion that estrogen is the growth factor that is
being over-expressed in cancer cells. As early as 1952, Nobel laureate Charles B.
Huggins showed that hormone deprivation brings some types of breast cancer into
remission (U.S. Dept, of Health and Human Services, 1984). The new strategy to fight
breast cancer became finding a way to stop estrogen from binding to receptors.
Researchers have identified the estrogen receptor on the surface of cells that regulate
transcription (Eng, 1998). They have developed a strategy to stop estrogen from binding
to those receptors. If a substance very similar to estrogen is pumped into the system, it

14

can bind to the estrogen receptor and take the place of estrogen. These dummy estrogen
molecules do not send any kind of signal to the cell’s nucleus and they block the
receptors, preventing real estrogen from sending a signal. Chemists alter the chemical
structure of estrogen molecules by adding hydroxyl, amino, nitro, or iodo groups to the
ring structure of estrogen (Brooks, 1997). Recall that DDT contains a molecule that was
so similar to estrogen that it actually sent a signal and caused the problem. The
molecules created by scientists had to be carefully tested to insure that they would bind to
the estrogen receptor but not actually cause a signal to be sent.
Hormone therapy using chemicals that mimic estrogen has been quite successful
with some types of breast cancer. However, not all tumor cells have estrogen receptors
on their surface. In tumors that have estrogen receptors, or estrogen-positive breast
cancers, hormone therapy causes more than half of breast cancers to go into complete
remission. Tumors with cells that do not contain estrogen receptors, estrogen-negative
cancers, are completely unaffected by hormone therapies (U.S. Dept, of Health and
Human Services, 1984). Research involving estrogen receptors has made more progress
than any other pursuit in breast cancer research, but there are clearly other types of breast
cancer and other explanations.
The p53 Gene and Apoptosis
A rare disorder called Li-Fraumeni syndrome has provided important clues for
another type of breast cancer. Li-Fraumeni is a rare genetic disorder found in only one
hundred families worldwide. Members of these families are prone too several types of
cancer, but breast cancer is the most common (Russell, 1998).
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Families with Li-Fniameni syndrome pass along a mutation in the p53 gene. This
mutation is present in healthy cells as well as tumor cells for those with this rare
hereditary difference. Studies of these patients may be key to solving the cause of cancer
in other patients. Some unrelated cancer patients suffer from the same type of cancer, a
tumor due to the same mutation in the p53 gene. It is important to note that people with
Li-Fraumeni syndrome have the p53 mutation in every cell in every organ of their body,
but they are not prone to every type of cancer. The mutation causes a problem with
programmed death, or apoptosis, that is specific to breast cells (Russell, 1998).
As discussed earlier, the p53 gene plays an instrumental role in apoptosis for cells
with a great deal of DNA damage. A new focus in cancer research revolves around
finding a way to cause cancer cells to continue into apoptosis. New compounds called
retinoid antagonists induce apoptosis. They have been found to be effective against all
types of breast cancer, irrespective of whether the tumor is estrogen-positive or estrogen
negative (Fanjul, 1998).
An interesting twist in reproductive health is that women who have children
earlier in life have a reduced risk of breast cancer, endometrial cancer, and ovarian
cancer. Many women in the developed world postpone childbirth to pursue career and
education. Postponing the first pregnancy has actually been identified as a risk factor.
Researchers suggest that this is because having children causes breast tissue cells
differentiate for a specific function. Differentiated cells are much less prone to abnormal
growth. As cells differentiate, they lose their ability to proliferate. Cells eventually reach
“terminal differentiation” and die. They are then replaced by stem cells and the pattern
continues as stem cells progress toward terminal differentiation (Russell, 1998). Proteins
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that trigger differentiation are may be signals to help the cell proceed through the cell
cycle normally, followed by apoptosis. Genes that regulate terminal differentiation may
be another source of DNA error that can contribute to problems with apoptosis.
IV. Detection and Treatment for Breast Cancer
Diagnosis
Patients are their own first lines of defense against breast cancer. Self
examinations can be the key to early detection and a better outcome. Cancer may take
the form of a lump or thickening in the breast or underarm area, or a change in size or
shape of the breast. Any change in color or feel of the skin should be checked as well.
Discharge from the nipple is also a dangerous predictor. It is still important to be
checked regularly by a health care professional, especially over age fifty. Simply being a
woman over the age of fifty is the best predictor of breast cancer.
A primary care physician or a physician’s assistant should provide information to
patients and encourage patients to get regular mammograms. Women often neglect
getting regular checkups because of fear, fatalism, cost, procrastination, or they are
simply unaware of the risks. Health care professionals may detect a problem by simple
palpation. It may even be possible to distinguish a benign tumor from a malignant tumor
by feel alone, although one would not rely on this method alone.
A mammogram is a much more reliable test. Mammographic imaging technique
is simply an X-ray of the breast that will show any abnormalities. All sites that offer
mammograms must comply with the Mammography Quality Standards Act, a set of
federal regulations to insure quality. Some physicians prefer to use ultrasonography, or
ultrasound. High frequency sound waves enter the breast and bounce back, creating a
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picture of the tissue. Ultrasound tests can be used to show whether a lump is solid or
fluid.
If the mammogram shows calcifications or any abnormalities, the patient needs
further tests. It is necessary to remove tissue to get an accurate diagnosis. A fine needle
aspiration, or needle biopsy, is the least intrusive procedure. A hollow needle draws out
fluid or a small amount of tissue. The specimen is sent to the pathology lab and a
pathologist sends back a diagnosis the next day. A surgical biopsy extracts more tissue.
A physician removes part or the entire suspicious lump. This tissue is also sent to the lab
for diagnosis by a pathologist.
Treatment
Surgery is usually the first treatment when breast cancer is detected, but it may be
used in conjunction with other methods such as chemotherapy, radiation therapy, or
hormonal manipulation. Chemotherapy uses drugs to kill cancer cells whereas radiation
therapy uses X-rays. These two methods can be a great aid for cases of very large
tumors. They can shrink the tumor so that the tumor can be removed more easily by
surgery. Hormone therapy attempts to combat the effects of estrogen and stop the
progression of tumors.
Progress in Treatments
At the end of the nineteenth century. Dr. William Halsted performed he first
mastectomies in the United States. He developed the procedure known as the radical
mastectomy, or Halsted procedure. The surgeon removes the breast and muscles of the
chest wall in order to remove the cancerous cells. The outcome was successful and
patients survived longer, but there were problems with the procedure. Removing muscle
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sometimes caused disability and swelling in the arms. Also, the procedure required large
incisions and some mastectomies left a large enough gap to necessitate skin grafts. The
radical mastectomy is considered outdated and is rarely used. Modem methods allow
surgeons to partially remove pectoral muscles if the cancer has reached the muscle, but
the disabilities caused by the Halsted procedure can be avoided.

Throughout the twentieth century, the trend in breast surgeries is to conserve
breast tissue and move toward a less intrusive procedure. The modified radical
mastectomy is a similar procedure developed in the 1960s. Surgeons remove breast
tissue and axillary lymph nodes but leave chest wall muscle intact. The incision is
smaller and the procedure is less disfiguring to the patient. The modified radical
mastectomy has the same success rate as the radical mastectomy. A simple mastectomy
is an even less imposing procedure that removes breast tissue but leaves muscle and
lymph nodes. This procedure is not common and can only be used in cases of very early
detection. By 1983, the National Surgical Adjuvant Breast Project developed the
procedure known as the lumpectomy, or quadrantectomy, which removes only the
cancerous part of the breast tissue and leaves the nipple and some breast tissue. Axillary
dissection, removal of the lymph nodes, is paired with a lumpectomy to remove all traces
of cancer.
Newer methods greatly improve the quality of life and psychological wellbeing of
the patient, but there are limits to their success. The new surgical procedures have not
actually lessened to number of people dying from cancer; they simply provide options for
cancer patients. Furthermore, a modified radical mastectomy is necessary in many cases.
A woman in her first of second trimester of pregnancy would not choose radiation

19

L

treatment that could harm the baby. A lumpectomy can not be used when more than one
tumor is present in different quadrants of the breast. In cases where the mammogram
shows calcifications which appear to be malignant, it is likely that cancerous cells are
dispersed throughout the breast and a modified radical mastectomy is the best choice to
ensure that all cancerous cells have been removed. The recurrence rate after a
mastectomy is 8 %, whereas surgeries that conserve part of the breast have a 10-15 %
recurrence rate after ten years (Mercy Health Services, 1999). However, if breast cancer
does return, a patient who still has breast tissue can always have a modified radical
mastectomy. A patient who had a mastectomy at the first occurrence of breast cancer
will have cancer recur in the pectoral muscles, which is more difficult to remove.
The Role of the Pathology Department
Unfortunately, surgery is not the end of the story for cancer victims. Once a
surgery has been performed, the hospital must confirm that the test has been successful.
If the surgery has not done a satisfactory job of removing cancerous cells, further
treatments are available (see Additional Treatments, below). In many cases, cancer
returns, especially when it has not been detected and treated early enough. Pathologists
give a prognosis for the likelihood that cancer will reappear. They may recommend
frequent checkups in the future if the results are questionable.
When the pathology laboratory receives tissue specimens from surgery,
pathologists conduct gross observation and dissect the tissue to collect information. They
note the size and shape of the tumor and the number of tumors if there are more than one.
The number of lymph nodes and the presence or absence of extracapsular lymph nodes is
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recorded. It is important to observe whether the tumor has invaded the lymphatic space.
This helps predict whether cancer has entered the lymphatic system.

Pathologists must make a judgement for how far the cancer has progressed. The
most popular system, developed by the American Joint Committee on Cancer
Classification, classifies the patient as stage 0,1, II, III, or IV. A cancer in the earliest
stages is referred to as a carcinoma in situ. It is non-invasive and is limited to a confined
area. Cancers that are confined to a small part of a duct, for example, may remain
dormant for years or it may never become invasive. If detected and removed during this
stage, cancer is considered to be cured and it is very unlikely to return (Altman and Sarg,
1992). Stage I cancer is confined to the breast area with a tumor no more than one inch
in diameter. Stage II cancer has spread to the underarm lymph nodes and has a slightly
larger tumor. In stage HI cancer patients, cancerous cells have spread to lymph nodes or
nearby breast tissues and the tumor is more than two inches in diameter. Stage IV cancer
is metastatic and has already spread to other organs (Cook and Dresser, 1996).
Metastasis is the stage when cancerous cells break off from the original tumor and
travel to other sites in the body through the blood or lymphatic systems. Common sites
for secondary tumors include the chest wall, local lymph nodes, brain, lungs, liver, bones
and central nervous system (Skarin, 1992). When a secondary tumor develops in another
part of the body it is still considered breast cancer because it consists of cells from breast
tissue (Cook, 1996). A pathologist must identify the type of cell that the tumor came
from. If the tumor is a secondary tumor from another part of the body, careful
identification of the type of cell can identify another cancerous site in the patient’s body.
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When the pathologist finishes these observations, he or she dissects the tissue and
removes representative samples for testing. A sample directly on the surgical margin will
be tested to determine if all of the cancerous cells have been removed. The hope is that
the tissue on the surgical margin is normal tissue, free of cancerous cells. Tissue samples
are removed at intervals throughout the tissue to find out the extent and multitude of
cancerous cells. Each lymph node must be removed for tests. Presence or absence of
cancer in the lymph nodes illustrates whether cancer has traveled to other parts of the
body. It is an important gage of the patient’s future health.
Tissues that the pathologist has chosen are processed overnight in the pathology
lab. Tissues are fixed in formylin and a series of alcohols, then permeated with wax. The
wax makes the tissues solid so that it can be sliced. The small block of wax with tissue
embedded in it is placed in a machine called a myotome, which slices the block into
strips that are four microns thick. This is thinner than the width of a red blood cell and
gives the doctors an excellent view of the tissue. This very thin strip of tissue is placed
on a glass slide. The slide goes through a series of stains. Different stains adhere to
different types of tissue, depending on the chemical properties of the tissue. The different
colors help distinguish one type of cell from another. The next morning, the pathologist
can look at a cross-section of the tissue under a microscope. This view of the cells under
the microscope gives all the information a pathologist needs to diagnose the cells as
cancerous or healthy.
The pathology lab may want to make extra slides of the tissue for special stains.
Histologists run special tests for estrogen or progesterone receptors. They use the
different chemical properties of each type of cell to determine if the cells are estrogen-
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positive or estrogen-negative. If the cells are estrogen-positive the patient has a type of
cancer that has been studied more, and the patient has more options for treatment.

Additional Treatment
Physicians use the observations and recommendations made by the pathologist to
plan further treatment. The report from the pathologists may reveal that cancerous cells
remain in the body even after surgery. Even if the cells appear to be free of cancer,
pathologists may recommend further treatment for severe cases when the cancer had
progressed through the stages to a dangerous level.
If physicians decide further treatment is necessary, they must decide whether they
are treating a patient who can be cured. In some patients, the cancer reaches an incurable
stage and the goal is simply to prolong life and sooth the symptoms. Chemotherapy may
not be worth it if the patient is too weak to handle the side effects. Hormonal therapy
may be a better option.
Other patients are curable, but they need additional therapy to exonerate all traces
of cancer. Treatments after surgery are known as adjuvant treatments. They may be
recommended for severe cases when there is a high risk that cancer will return. Patients
have adjuvant treatments tailored to their needs, but a typical treatment would be
chemotherapy for four to six months, hormonal therapy for five years, or possibly both.
Adjuvant treatments intend to permanently rid the body of cancer.
Radiation therapy is commonly used after surgery to get rid of remaining cancer
cells and prevent the return of cancer. Treatment is recommended when the pathologist
reports a tumor greater than five centimeters, a tumor that has invaded the skin or chest
wall, surgical margins that are cancerous, and multiple metastatic lymph nodes.

23

Radiation treatment allows surgeons to perform surgeries that conserve more of the
patient’s breast, then follow up with radiation treatment. It is especially preferable when
cancer has invaded muscle in the chest wall. Removal of that muscle could leave the
patient with limited arm movement, while radiation will leave the muscle intact.
Radiation treatment can begin as soon as surgical scars have healed. A common
radiation treatment program is thirty to thirty-five daily treatments over a seven-week
period.
Bone marrow transplants attempt to conserve bone marrow stem cells that could
be killed by the chemotherapy or radiation therapy. Stem cells are removed before
chemotherapy begins and replaced after the treatments are over. The procedure is very
dangerous and a few patients die of the procedure. Bone marrow transplants are actively
being researched and may become more common in the future.
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